Public Policy & Advocacy

Responsible lobbying

We strive to engage in constructive dialogue with policymakers and other external stakeholders with the intent to represent the perspective of Novartis in the policy making process. We provide policymakers with data and insights to enable widely informed decision-making. We undertake political activities in a responsible and ethical manner with a view to creating a sustainable business environment that is conducive to improving patient outcomes.

We strive to engage in constructive dialogue with policymakers and other external stakeholders with the intent to represent the perspective of Novartis in the policy making process. We provide policymakers with data and insights to enable widely informed decision-making. We undertake political activities in a responsible and ethical manner with a view to creating a sustainable business environment that is conducive to improving patient outcomes.

What we lobby for:

• Solid protection of intellectual property that incentivizes investment in pharmaceutical research and development (R&D), enables knowledge sharing and allows rapid market access for generic and biosimilar medicines after loss of exclusivity
• An agile regulatory framework that champions new science and embraces opportunities from digitalization in healthcare while protecting patient safety and privacy
• Rapid patient access to innovation and quality medicines through universal health coverage and solid drug distribution pathways with affordable copay
• Increased efficiency in healthcare systems, through stringent focus on healthcare outcomes, reflected in their general payment policies, as well as in value assessment frameworks for pharmaceuticals
• A global trade and business environment that facilitates a global approach to R&D and manufacturing through open markets, non-discrimination and tax frameworks, acknowledging high risks and long cycle investments

Our guide to responsible lobbying

We are guided by three principles when conducting responsible lobbying:

• Principle 1: Transparency, honesty and integrity are the core values reflected in how Novartis conducts lobbying.
• Principle 2: All lobbying activities should enable widely informed decision making conducive to improving patient outcomes and Novartis sustainable business in pursuit of the company purpose.
• Principle 3: Novartis associates must not attempt to improperly influence any decision by inducing lobbied stakeholders to act or not to act in violation of their lawful duties.

Read the Novartis Global Guideline (PDF 0.1 MB) for responsible lobbying

Political engagement

Novartis Group companies maintain full-time Public Affairs offices in several locations, including our Group Headquarters in Basel, Switzerland, Brussels, Belgium and Washington, D.C. in the United States.  Our Public Affairs associates assess regulatory and political decisions with a potential impact on our business and on our patients across the globe. 

We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice and help foster framework conditions favorable to investment into R&D. In 2016, Novartis Group companies contributed USD 55.9 million to various major international, regional and country trade associations. Our list of memberships is available in the Novartis in Society report (PDF 0.3 MB).

Governance

All Novartis associates and third parties retained by Novartis to lobby on behalf of the company must act in accordance with the principles and rules established in the Novartis guideline on responsible lobbying.  Training is provided to all associates engaged in lobbying, in Corporate Affairs as well as in related functions. Steps are being taken to strengthen the due diligence for all third parties engaging with political stakeholders.

Overall Novartis political engagement is - like any other Novartis activity - governed globally by Novartis code of conduct and its subsequent policies such as the antibribery policy and the third party guideline. All Novartis policies and guidelines are being monitored as part of Novartis auditing mechanisms. 

Political contributions

Novartis makes financial contributions to support political dialogue on issues of relevance to the company, or to certain government projects, e.g. for capacity-building. Political contributions made by the company are not intended to give rise to any obligations on the part of the recipients, nor with the expectation of a direct or immediate return for Novartis. Such contributions need to be fully compliant with applicable laws, regulations and industry codes. We only make political contributions in countries where such contributions by corporations are both legal and generally considered appropriate.

In 2018, Novartis made political contributions totaling approximately USD 1.85 million, of which approximately USD 626 000  were made in Switzerland, USD 1.14 million in the US (including political contributions made through the Novartis Political Action Committee), USD 67 000 in Australia and USD 10 000 in Japan.  In Switzerland, Novartis supports political parties with a political agenda and positions supporting the strategic interests of the company in pursuit of the company mission.  Swiss political parties are completely privately financed, and corporate contributions are crucial.  The private financing of parties is a deeply rooted trait of Swiss political culture, and contributing to the system is an important element of being a good corporate citizen. 

Novartis Political Action Committee

Integral to the US political system is the role of political action committees (PACs). As such, the Novartis PAC, a voluntary, non-partisan organization, was formed to financially support the election of qualified candidates for public office who have an interest in working on policy issues important to Novartis, demonstrated political leadership or represent a state or district where the company has a facility or a large concentration of employees. Members of the Novartis PAC are eligible employees. The Novartis PAC only uses funds received from individual participating employees (but not from the company) to make political contributions. The PAC is independent of any political party, candidate or other organization. Novartis PAC may contribute to federal, state, and local candidate campaigns, party committees and Leadership PACs at any time during an election cycle. The PAC is subject to federal contribution limits established by the US Federal Election Commission (e.g., USD 5,000 to each candidate or candidate committee per election). Administration of the Novartis PAC is clearly defined in terms of soliciting contributions, determining candidates to receive financial support, disbursement of funds and reporting.

For more information on our political contributions in the US, read the Novartis in Society US report (PDF 1.5 MB)

Disclosure of political funding and lobbying

Novartis discloses political contributions as required by law, such as in the US or Ireland. To provide lobbying transparency, Novartis is listed in the Register of Interest Representatives, the European Commission’s voluntary self-regulation system. Accordingly, Novartis has committed to publish a yearly estimate of the costs associated with lobbying of the EU institutions and subscribe to the Commission’s Code of Conduct. Novartis also files quarterly activity reports with the Clerk of the US House of Representatives and Secretary of the US Senate.